Wave Life Sciences Highlights WVE-007 (INHBE siRNA) Progress at ObesityWeek® 2026
Globe Newswire•13/11/2026•08:30 ET
0
Key Highlights
- ➤WVE-007 single-dose Activin E reductions reached mean maximums of 82%-88%.
- ➤WVE-007 Phase 1 showed no drug-related serious adverse events or discontinuations.
- ➤240 mg cohort maintained visceral-fat and waist reductions with lean-mass preservation after one year.
- ➤Wave expects six-month Phase 2a monotherapy data in 2027.
- ➤Wave plans to integrate its maintenance trial with the ongoing tirzepatide combination trial.
Expert Statements
Christopher Wright, Chief Medical Officer, Wave Life Sciences
“The Phase 1 single-dose portion of our INLIGHT clinical trial continues to demonstrate that WVE-007 impacts the desired biology with potent, durable Activin E reductions leading to body composition improvements and a favorable safety profile.”
Christopher Wright, Chief Medical Officer, Wave Life Sciences
“We continue to advance our ongoing higher BMI Phase 2a monotherapy trial, which is evaluating WVE-007’s potential to expand the treatment landscape for obesity, particularly for individuals who need an alternative to incretins.”
Christopher Wright, Chief Medical Officer, Wave Life Sciences
“We expect six-month follow-up data in 2027, which will include body composition measurements as well as liver fat changes that could accelerate development in MASH.”
Christopher Wright, Chief Medical Officer, Wave Life Sciences
“In parallel, we are also investigating WVE-007 as a complementary approach to enhance fat loss with incretins, and as a post-incretin weight maintenance strategy.”
INLIGHT Phase 1 data continue to support WVE-007’s novel mechanism of action to improve body composition by inducing fat loss without muscle loss, and support a once- or twice-yearly dosing regimen
Six-month data from ongoing Phase 2a monotherapy trial in individuals with high BMI, high adiposity, and comorbidities anticipated in 2027
Get started
Create a free account to read the full story.